{"gene":"AXIN2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2002,"finding":"Axin2 is a direct transcriptional target of the Wnt/β-catenin pathway, activated through TCF/LEF binding sites in its promoter and first intron. Mutation or deletion of TCF/LEF sites greatly diminished induction by β-catenin, and mutation of site T2 abolished protein binding in an EMSA. This establishes Axin2 as part of a negative feedback loop that limits Wnt signal duration/intensity.","method":"Reporter constructs with 5.6-kb genomic fragment, TCF/LEF site mutagenesis, EMSA, transgenic embryo analysis, endogenous mRNA/protein induction assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (EMSA, mutagenesis, reporter assays, transgenic validation) in a single rigorous study, replicated by independent lab (PMID:11940574)","pmids":["11809808","11940574"],"is_preprint":false},{"year":2002,"finding":"AXIN2 expression is strongly induced by activated β-catenin-TCF signaling via TCF binding sites in the AXIN2 promoter; dominant-negative TCF-4 represses AXIN2 expression. Restoration of wild-type APC suppresses AXIN2. This positions AXIN2 in a negative feedback pathway regulating Wnt signaling, distinct from AXIN1 which is not regulated by β-catenin-TCF.","method":"β-catenin-estrogen receptor fusion activation, Wnt1 overexpression, dominant-negative TCF-4, APC restoration, TCF binding site reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (inducible β-catenin, Wnt1, dnTCF-4, APC restoration, reporter assays), independently replicated (PMID:11809808)","pmids":["11940574"],"is_preprint":false},{"year":2005,"finding":"Axin2 and Axin1 proteins are functionally equivalent in vivo. Knockin mice expressing Axin2 cDNA under the Axin1 locus (Axin^Ax2/Ax2) are apparently normal and fertile, demonstrating that the lack of redundancy between the two proteins in wild-type animals is due to their different expression patterns rather than different protein functions.","method":"Knockin mouse generation (Axin cDNA replaced with Axin2 cDNA), viability and fertility assessment of homozygous knockin mice","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean in vivo genetic rescue with defined phenotypic readout (viability/fertility), robust experimental design","pmids":["15899843"],"is_preprint":false},{"year":2005,"finding":"Axin2 is expressed at osteogenic fronts and periosteum of developing sutures; targeted disruption of Axin2 in mice causes craniosynostosis through enhanced β-catenin signaling, increased osteoprogenitor expansion, accelerated ossification, and stimulated osteoblast proliferation and differentiation. The craniofacial anomalies are mediated through activation of β-catenin signaling.","method":"Axin2 knockout mice, in vivo/in vitro osteoblast differentiation assays, β-catenin signaling analysis, osteogenic marker expression","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined mechanistic pathway (β-catenin activation), multiple cellular phenotype readouts, in vitro validation","pmids":["15790973"],"is_preprint":false},{"year":2010,"finding":"Conductin/Axin2 localizes at centrosomes by binding to the centriole-associated component C-Nap1. Knockout or knockdown of conductin leads to premature centrosome separation (splitting), which is abolished by knockdown of β-catenin. Conductin promotes phosphorylation of N-terminal serine/threonine residues (Ser33/37, Thr41) of centrosome-associated β-catenin; β-catenin mutated at these residues causes centrosomal splitting. Treatment with Wnts and GSK3 inhibition block β-catenin phosphorylation and induce centrosomal splitting.","method":"Conductin KO/KD, β-catenin KD, centrosome localization imaging, phospho-β-catenin mutant analysis, Wnt/GSK3 inhibitor treatment","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal KO/KD with mechanistic follow-up (phospho-mutants, C-Nap1 binding), multiple orthogonal methods","pmids":["20300119"],"is_preprint":false},{"year":2011,"finding":"Axin2 function is essential for normal kinetics of oligodendrocyte progenitor cell (OLP) differentiation and remyelination after injury. The small molecule tankyrase inhibitor XAV939 stabilizes Axin2 levels in OLPs and accelerates their differentiation and myelination after hypoxic and demyelinating injury.","method":"Axin2 loss-of-function in vivo, XAV939 (tankyrase inhibitor) treatment of OLPs from brain and spinal cord, remyelination assays after hypoxic/demyelinating injury","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined remyelination phenotype plus pharmacological rescue with mechanistic basis (Axin2 stabilization via tankyrase inhibition)","pmids":["21706018"],"is_preprint":false},{"year":2012,"finding":"Conductin/Axin2 levels peak at G2/M and are rapidly degraded during return to G1. Conductin is degraded by the APC/C cofactor CDC20. CDC20 knockdown blocks Wnt signaling through conductin. CDC20-resistant conductin inhibits Wnt signaling and attenuates colony formation. β-catenin phosphorylation oscillates during the cell cycle in a conductin-dependent manner.","method":"Cell cycle synchronization, CDC20 knockdown, CDC20-resistant conductin mutant expression, Wnt signaling reporters, colony formation assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — identified specific E3 ligase component (CDC20/APC-C) as conductin writer/eraser, validated with resistant mutant and KD, multiple readouts","pmids":["22322943"],"is_preprint":false},{"year":2012,"finding":"Axin2 promotes colon carcinoma oncogenic activity (rather than acting as a tumor suppressor) by upregulating the transcriptional repressor Snail1, inducing epithelial-mesenchymal transition (EMT) and driving metastatic activity. Silencing Axin2 decreases Snail1 activity, reverses EMT, and inhibits CRC invasive and metastatic activities.","method":"Axin2 silencing in CRC cells, Snail1 activity assays, EMT marker analysis, invasion and metastasis assays in vitro and in vivo, Wnt-regulated transcriptome analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined molecular pathway (Axin2→Snail1→EMT), multiple orthogonal phenotypic readouts","pmids":["22745173"],"is_preprint":false},{"year":2009,"finding":"Axin2 is a key negative regulator of bone remodeling in adult mice; its loss increases trabecular bone mass and bone formation rates, and increases nuclear β-catenin in BMS cells. Axin2 KO-enhanced osteoblast differentiation is reversed by β-catenin deletion. Axin2 regulates osteoblast differentiation through the β-catenin-BMP2/4-Osterix signaling pathway.","method":"Axin2 KO mice, bone marrow stromal cell isolation, in vitro β-catenin deletion rescue, BMP2/4 mRNA and pSmad1/5 analysis, GSK3β inhibitor BIO treatment, Bmp2/4 conditional deletion","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with defined bone phenotype, genetic rescue (β-catenin deletion), BMP2/4 pathway downstream validation, pharmacological confirmation","pmids":["19737815"],"is_preprint":false},{"year":2011,"finding":"The Axin2(canp) V26D substitution in an N-terminal sequence motif results in a more stable Axin2 protein. Increased stability of Axin2 generally decreases Wnt signaling in most tissues but paradoxically enhances canonical Wnt activity in the late primitive streak. Treatment of wild-type embryos with a tankyrase inhibitor that stabilizes Axin proteins phenocopies this, confirming that Axin2 stability is a key regulatory mechanism.","method":"ENU-induced Axin2(canp) allele characterization, protein stability assays, tissue-specific Wnt signaling reporter analysis, tankyrase inhibitor treatment of embryos","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single lab, allelic characterization plus pharmacological validation, but mechanistic basis of tissue-specific paradoxical activation not fully resolved","pmids":["21555575"],"is_preprint":false},{"year":2017,"finding":"Axin2 functions upstream of Rap1b in skeletal development: Axin2 regulates Rap1b through modulation of canonical BMP signaling. Rap1b acts as a signaling integrator for FGF and BMP downstream of Axin2; BMP-mediated activation of Rap1b promotes chondrogenic fate and inhibits MAPK/FGF-driven osteoblast differentiation.","method":"Genetic analysis of Rap1b-null mice, Axin2+ stem cell characterization, BMP/FGF signaling pathway analysis, osteogenic/chondrogenic differentiation assays","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined epistatic relationship (Axin2→BMP→Rap1b) with genetic KO validation, single lab","pmids":["28520221"],"is_preprint":false},{"year":2013,"finding":"Runx2 represses Axin2 transcription via Hdac3, by binding to multiple regions of the Axin2 promoter. Runx2 haploinsufficiency in Axin2-null mice rescues the craniosynostosis phenotype, placing Runx2 upstream of Axin2 in a pathway regulating intramembranous bone development.","method":"ChIP (Runx2 binding to Axin2 promoter), Hdac3-dependent repression assays, Axin2(-/-):Runx2(+/-) double mutant mice, skull morphology analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP identifying direct promoter binding, genetic epistasis via double-mutant rescue, Hdac3 functional dependency established","pmids":["23300083"],"is_preprint":false},{"year":2015,"finding":"In satellite cells (muscle stem cells), Axin1 and Axin2 have non-equivalent functions: Axin1 knockdown in Axin2-null cells strongly inhibits proliferation, induces differentiation, causes nuclear β-catenin localization, and activates TCF reporter activity. These effects are rescued by concomitant β-catenin knockdown, demonstrating that Axin1 and Axin2 cooperate to suppress β-catenin signaling and maintain myoblast proliferation.","method":"siRNA knockdown of Axin1 and Axin2 in WT and Axin2-null satellite cells, β-catenin localization/reporter assays, retroviral Axin2 overexpression, proliferation/differentiation assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (double KD + β-catenin rescue), Axin2-null cells, TCF reporter, single lab","pmids":["25866367"],"is_preprint":false},{"year":2004,"finding":"Axin2 mRNA contains alternative 5'-untranslated regions (5'UTRs) that differentially regulate translational efficiency via short upstream reading frames and structural motifs. Proportional expression of each 5'UTR variant influences total Axin2 protein levels, establishing a translational control mechanism for Axin2 expression.","method":"5'UTR reporter constructs, mRNA stability assays, translational efficiency measurements, characterization of upstream ORFs and secondary structures","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro/cell-based mechanistic dissection of 5'UTR regulatory elements, single lab with multiple readouts","pmids":["15611123"],"is_preprint":false},{"year":2019,"finding":"An aggregation site (aggregon) in the RGS domain of conductin/Axin2 prevents its polymerization and limits its activity relative to Axin1. Point mutations that neutralize this aggregon enhance conductin polymerization and β-catenin degradation. A short peptide that masks the aggregon induces conductin polymerization, enhances β-catenin degradation, inhibits β-catenin-dependent transcription, and represses colorectal cancer cell growth.","method":"Domain swapping between Axin1 and Axin2, point mutagenesis of aggregon, polymerization assays, β-catenin degradation assays, Wnt reporter assays, colorectal cancer cell growth assays, peptide treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain swapping, mutagenesis, reconstitution of polymerization, multiple functional readouts (β-catenin degradation, transcription, cell growth)","pmids":["31534175"],"is_preprint":false},{"year":2022,"finding":"Gαi2 induces conductin/Axin2 condensation by targeting the polymerization-inhibiting aggregon in its RGS domain, thereby promoting conductin-mediated β-catenin degradation and inhibiting Wnt signaling. Transient Gαi2 expression inhibits Wnt signaling, Gαi2 knockdown activates it, and the Gαi2-activating drug guanabenz inhibits Wnt signaling via conductin, reducing colorectal cancer growth in vitro and in mouse models.","method":"Gαi2 overexpression/knockdown, conductin condensation assays, β-catenin degradation assays, Wnt reporter assays, guanabenz drug treatment, colorectal cancer mouse models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — identification of Gαi2 as a conductin binding partner/activator with mechanistic follow-up (aggregon targeting, condensate formation), in vitro + in vivo validation","pmids":["35115535"],"is_preprint":false},{"year":2017,"finding":"AXIN2 is required for degradasome formation and β-catenin degradation upon tankyrase inhibition in SW480 cells. AXIN1 is not required for degradasome formation, whereas depletion of AXIN2 considerably impairs both degradasome formation and their capacity to degrade β-catenin. This reveals a differential and non-redundant role for AXIN2 (vs AXIN1) in the β-catenin destruction complex.","method":"siRNA depletion of AXIN1 and AXIN2 in SW480 cells, tankyrase inhibitor G007-LK treatment, degradasome imaging, β-catenin degradation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single lab, reciprocal depletion with defined cellular phenotype, functional readout (β-catenin degradation)","pmids":["28107521"],"is_preprint":false},{"year":2007,"finding":"TGF-β suppresses the expression of both Axin1 and Axin2 in chondrocytes through a Smad3-dependent mechanism. In Axin2(-/-) chondrocytes, TGF-β treatment results in a sustained increase in β-catenin levels compared to wild-type. Overexpression of Axin2 enhances TGF-β signaling while overexpression of β-catenin inhibits Smad3-sensitive reporters, demonstrating that Axin2 mediates cross-talk between TGF-β and Wnt/β-catenin signaling pathways.","method":"Axin2(-/-) and Smad3(-/-) chondrocytes, TGF-β treatment, Smad3-sensitive reporter assays, β-catenin measurement, Axin overexpression","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO cells with defined pathway cross-talk, Smad3 genetic dependency, single lab","pmids":["18083923"],"is_preprint":false},{"year":2008,"finding":"Epigenetic silencing of AXIN2 through TGF-β-dependent increase in AXIN2 mRNA decay reduces Axin2 protein levels in systemic sclerosis fibroblasts, causing sensitization to canonical Wnt ligands. XAV939-mediated stabilization of Axin2 (via tankyrase inhibition) reverses the increased Wnt response, demonstrating that reduced Axin2 bioavailability is the mechanistic basis for TGF-β-primed Wnt activation.","method":"TGF-β treatment of fibroblasts, Axin2 mRNA decay assays, TGFβRI blockade, siRNA-mediated tristetraprolin1 depletion, XAV939 treatment, TOPflash reporter assays, Axin2 gain/loss-of-function","journal":"Arthritis & rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mRNA decay mechanism identified, in vivo TβRIIΔk-fib transgenic mouse validation, multiple orthogonal methods, single lab","pmids":["29409120"],"is_preprint":false},{"year":2023,"finding":"Axin2 suppresses the p53 signaling pathway at the post-transcriptional level to maintain neural progenitor cell (NPC) fitness. In a mosaic setting, Axin2-deficient NPCs behave as 'losers' and undergo p53-dependent apoptotic elimination via cell competition. Homogeneous Axin2 ablation does not promote cell death. Conditional loss of both Axin2 and Trp53 increases cortical area and thickness.","method":"Mosaic genetic mosaicism induction, Axin2-conditional KO, p53/Trp53 conditional KO, double conditional KO, NPC apoptosis quantification, cortical size measurement","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — mosaic vs. homogeneous KO distinguishes cell competition mechanism, genetic double KO epistasis, defined cellular and developmental phenotype","pmids":["37054704"],"is_preprint":false},{"year":2023,"finding":"Axin2 interacts with the glycolytic enzyme enolase 1 (ENO1) in ASD neurons. An Axin2 stabilizer (XAV939) blocked the Axin2/ENO1 interaction, switched glycolysis/oxidative phosphorylation balance, promoted synaptic maturation, and rescued social function in ASD mouse models.","method":"Co-interaction assays for Axin2/ENO1, XAV939 treatment, glycolysis measurement, synaptic maturation assays, behavioral testing in Shank3(-/-) and VPA-treated mice","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel binding partner identified (ENO1), pharmacological disruption with functional readout, in vivo behavioral rescue, single lab","pmids":["37078424"],"is_preprint":false},{"year":2007,"finding":"Overexpression of wild-type AXIN2 inhibits Wnt-3a-stimulated TCF/LEF-dependent transcription in medulloblastoma cells. In contrast, an AXIN2 mutant with a deleted C-terminal DIX domain activates the Wnt signaling pathway, demonstrating that the DIX domain is required for Axin2's inhibitory function on Wnt signaling.","method":"Wild-type and DIX-domain-deleted AXIN2 overexpression in MB cell lines, luciferase Wnt reporter assays, Wnt-3a stimulation","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — domain deletion mutagenesis with functional reporter readout, single lab","pmids":["17373666"],"is_preprint":false},{"year":2019,"finding":"ALKBH5, an RNA N6-methyladenosine (m6A) eraser, binds and demethylates AXIN2 mRNA, causing its dissociation from the m6A reader IGF2BP1 and subsequent degradation. Loss of AXIN2 mRNA stability results in hyperactivated Wnt/β-catenin signaling, increased DKK1, and MDSC-driven immunosuppression in colorectal cancer.","method":"Methylated RNA immunoprecipitation sequencing, RNA sequencing, ALKBH5 knockin mice, allografts, CD34+ humanized mice, flow cytometry, in vitro/in vivo functional assays","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — meRIP-seq identifies AXIN2 as ALKBH5 substrate, IGF2BP1 reader mechanism characterized, multiple in vivo models validate functional consequence","pmids":["37169182"],"is_preprint":false},{"year":2019,"finding":"CDX2 transcriptionally activates AXIN2 expression by directly binding to an upstream enhancer of AXIN2, as confirmed by dual-luciferase reporter and quantitative ChIP assays. CDX2 knockdown reduces AXIN2 expression and enhances Wnt/β-catenin signaling, while CDX2 overexpression increases AXIN2 and suppresses Wnt signaling.","method":"Dual-luciferase reporter assay, quantitative ChIP, CDX2 knockdown/overexpression, Wnt pathway activity assays (TOP/FOP-Flash), β-catenin target gene expression","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — qChIP identifies direct CDX2 binding to AXIN2 enhancer, functional reporter validation, single lab","pmids":["30631044"],"is_preprint":false},{"year":2013,"finding":"CDX2 activates AXIN2 promoter activity via intestinal cell-specific enhancer elements, as shown by transfection of intestinal and non-intestinal cell lines. Suppressed CDX2 is associated with endogenous downregulation of AXIN2 expression in Caco-2 cells, confirming CDX2 as a transcriptional activator of AXIN2.","method":"Promoter-enhancer reporter transfection assays, CDX2 knockdown, endogenous AXIN2 mRNA quantification","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — reporter assays plus endogenous expression validation, replicated by PMID:30631044, single method per study","pmids":["23393221"],"is_preprint":false},{"year":2018,"finding":"TGF-β activation decreases Axin2 expression in fibroblasts through a TGF-β-dependent increase in Axin2 mRNA decay, mediated by tristetraprolin 1. This reduction in Axin2 bioavailability is necessary for TGF-β to prime canonical Wnt signaling. In vivo validation in TβRIIΔk-fib transgenic mice confirms decreased Axin2 mRNA and protein in fibroblasts with dysregulated TGF-β signaling.","method":"mRNA decay assays, siRNA knockdown of tristetraprolin 1, TGFβRI blockade, Axin2 gain/loss-of-function, TOPflash assay, TβRIIΔk-fib transgenic mouse analysis","journal":"Arthritis & rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic identification of mRNA decay pathway, in vivo transgenic mouse confirmation, single lab","pmids":["29409120"],"is_preprint":false}],"current_model":"AXIN2 (conductin/Axil) is a scaffold protein and direct transcriptional target of the Wnt/β-catenin-TCF/LEF pathway that functions in a negative feedback loop: upon Wnt activation, β-catenin-TCF drives AXIN2 transcription, and the resulting AXIN2 protein joins the β-catenin destruction complex (with APC, GSK-3β, CK1) to promote β-catenin phosphorylation and proteasomal degradation; AXIN2 protein levels are further regulated post-translationally by CDC20/APC-C-mediated degradation at G2/M, by tankyrase-mediated ubiquitination, and by a polymerization-inhibiting aggregon in its RGS domain that is relieved by Gαi2 binding; AXIN2 also localizes to centrosomes via C-Nap1 to regulate β-catenin phosphorylation and centrosome cohesion, interacts with ENO1 to modulate glycolysis/oxidative phosphorylation balance, suppresses p53 signaling post-transcriptionally to maintain cell fitness during neural progenitor cell competition, and acts through Rap1b to integrate BMP and FGF cross-talk in skeletal development; additionally, in certain cancer contexts AXIN2 promotes EMT and metastasis by upregulating Snail1, revealing context-dependent pro- and anti-tumorigenic roles."},"narrative":{"mechanistic_narrative":"AXIN2 (conductin/Axil) is a scaffold protein that operates as the central node of a negative feedback loop in Wnt/β-catenin signaling: it is itself a direct transcriptional target of β-catenin-TCF/LEF, induced through TCF/LEF sites in its promoter and first intron, and the resulting protein joins the β-catenin destruction complex to drive β-catenin N-terminal phosphorylation (Ser33/37, Thr41) and degradation, thereby limiting Wnt signal duration [PMID:11809808, PMID:11940574, PMID:20300119]. AXIN2 and AXIN1 are functionally interchangeable proteins whose distinct biology derives from differing expression rather than intrinsic function [PMID:15899843], yet AXIN2 has non-redundant, context-specific roles — it is selectively required for degradasome formation upon tankyrase inhibition [PMID:28107521] and cooperates with AXIN1 to restrain β-catenin in stem cell pools [PMID:25866367]; its inhibitory activity depends on the C-terminal DIX domain [PMID:17373666]. AXIN2 activity is tightly tuned at multiple post-transcriptional levels: a polymerization-inhibiting aggregon in its RGS domain limits its assembly and β-catenin-degrading capacity, a constraint relieved by Gαi2-induced condensation [PMID:31534175, PMID:35115535]; its protein level oscillates across the cell cycle through APC/C-CDC20-mediated degradation at the G2/M-to-G1 transition [PMID:22322943]; and its stability and mRNA abundance are controlled by tankyrase, alternative 5'UTRs, and TGF-β-driven mRNA decay and m6A-dependent turnover [PMID:21555575, PMID:15611123, PMID:29409120, PMID:37169182]. Through this circuitry AXIN2 governs skeletal development and bone remodeling — its loss causes craniosynostosis and increased bone mass via β-catenin-BMP2/4-Osterix signaling and a Rap1b-integrated BMP/FGF axis — and is itself transcriptionally controlled by Runx2 and CDX2 [PMID:15790973, PMID:19737815, PMID:28520221, PMID:23300083, PMID:30631044]. Beyond canonical Wnt regulation, AXIN2 localizes to centrosomes via C-Nap1 to maintain centrosome cohesion [PMID:20300119], suppresses p53 signaling post-transcriptionally to sustain neural progenitor fitness during cell competition [PMID:37054704], and interacts with the glycolytic enzyme ENO1 to modulate glycolysis/oxidative phosphorylation balance [PMID:37078424]. In cancer it shows context-dependent roles, acting as a tumor suppressor whose enforced polymerization restrains colorectal cancer growth [PMID:31534175, PMID:35115535] yet, in other contexts, promoting EMT and metastasis by upregulating Snail1 [PMID:22745173].","teleology":[{"year":2002,"claim":"Established that AXIN2 is a direct β-catenin-TCF transcriptional target, defining the negative feedback architecture that distinguishes it from AXIN1.","evidence":"Reporter constructs, TCF/LEF site mutagenesis, EMSA, transgenic embryos, and inducible β-catenin/Wnt1/dnTCF-4 perturbation","pmids":["11809808","11940574"],"confidence":"High","gaps":["Does not address how AXIN2 protein engages the destruction complex","Does not resolve tissue-specific differences in feedback strength"]},{"year":2005,"claim":"Showed AXIN2 and AXIN1 proteins are functionally equivalent in vivo, attributing their non-redundancy to expression patterns rather than protein function.","evidence":"Knockin mice expressing Axin2 cDNA from the Axin1 locus, scored for viability and fertility","pmids":["15899843"],"confidence":"High","gaps":["Whole-organism rescue does not exclude cell-type-specific functional differences later observed in stem cells and degradasomes"]},{"year":2005,"claim":"Linked AXIN2 to skeletal development, showing its loss causes craniosynostosis via enhanced β-catenin-driven osteoprogenitor expansion.","evidence":"Axin2 knockout mice with osteoblast differentiation and β-catenin signaling readouts","pmids":["15790973"],"confidence":"High","gaps":["Does not define upstream transcriptional control of Axin2 in sutures","Downstream osteogenic effectors not yet mapped"]},{"year":2009,"claim":"Extended AXIN2's skeletal role to adult bone remodeling and identified the β-catenin-BMP2/4-Osterix axis as the effector pathway.","evidence":"Axin2 KO mice, BMS cell differentiation, β-catenin deletion rescue, BMP2/4 conditional deletion, GSK3β inhibitor treatment","pmids":["19737815"],"confidence":"High","gaps":["Does not establish whether BMP2/4 induction is direct or secondary to β-catenin"]},{"year":2010,"claim":"Identified a non-canonical centrosomal role: AXIN2 binds C-Nap1 and locally phosphorylates β-catenin to maintain centrosome cohesion.","evidence":"Conductin KO/KD, β-catenin KD, centrosome imaging, phospho-mutant β-catenin analysis, Wnt/GSK3 inhibitor treatment","pmids":["20300119"],"confidence":"High","gaps":["Does not define how Wnt signaling temporally couples to centrosome splitting","Structural basis of C-Nap1 binding unknown"]},{"year":2012,"claim":"Revealed cell-cycle control of AXIN2 abundance via APC/C-CDC20 degradation at G2/M, coupling Wnt signaling output to the cell cycle.","evidence":"Cell-cycle synchronization, CDC20 knockdown, CDC20-resistant conductin mutant, Wnt reporters, colony formation assays","pmids":["22322943"],"confidence":"High","gaps":["Degron sequence recognized by CDC20 not fully mapped","Physiological consequence of cell-cycle Wnt oscillation in vivo unclear"]},{"year":2012,"claim":"Demonstrated a context-dependent oncogenic role in which AXIN2 drives EMT and metastasis through Snail1 upregulation, contrary to its canonical tumor-suppressor activity.","evidence":"AXIN2 silencing in CRC cells, Snail1 and EMT marker assays, in vitro/in vivo invasion and metastasis assays","pmids":["22745173"],"confidence":"High","gaps":["Molecular basis for the switch between suppressive and oncogenic roles not defined","Whether Snail1 regulation is β-catenin-dependent unresolved"]},{"year":2007,"claim":"Mapped the DIX domain as required for AXIN2's Wnt-inhibitory function, since DIX deletion converts AXIN2 into a pathway activator.","evidence":"Wild-type vs DIX-deleted AXIN2 overexpression with luciferase Wnt reporters in medulloblastoma cells","pmids":["17373666"],"confidence":"Medium","gaps":["Single-domain deletion; does not reconcile DIX with the later-described RGS aggregon control of polymerization"]},{"year":2007,"claim":"Positioned AXIN2 as a mediator of TGF-β/Wnt cross-talk in chondrocytes through Smad3-dependent suppression of Axin expression.","evidence":"Axin2-/- and Smad3-/- chondrocytes, TGF-β treatment, Smad3 reporters, Axin/β-catenin overexpression","pmids":["18083923"],"confidence":"Medium","gaps":["Mechanism of Smad3-dependent Axin2 repression not detailed","Single lab"]},{"year":2011,"claim":"Established AXIN2 protein stability as a key tunable regulatory parameter, with tankyrase-dependent stabilization controlling tissue-specific Wnt output.","evidence":"ENU Axin2(canp) V26D stable allele, protein stability and tissue Wnt reporters, tankyrase inhibitor treatment of embryos; and OLP loss-of-function with XAV939 remyelination rescue","pmids":["21555575","21706018"],"confidence":"Medium","gaps":["Mechanistic basis for paradoxical tissue-specific Wnt activation unresolved","Link between stability motif and tankyrase pathway not fully defined"]},{"year":2013,"claim":"Defined transcriptional control of AXIN2 by Runx2-Hdac3 repression and CDX2 activation, embedding it in bone and intestinal regulatory circuits.","evidence":"ChIP for Runx2 and CDX2 binding, Hdac3-dependent repression assays, Axin2-/-:Runx2+/- rescue, intestinal enhancer reporters","pmids":["23300083","23393221"],"confidence":"High","gaps":["Interplay between repressive (Runx2) and activating (CDX2, β-catenin) inputs at the locus not integrated"]},{"year":2015,"claim":"Showed AXIN1 and AXIN2 are non-equivalent in satellite cells, cooperating to suppress β-catenin and maintain myoblast proliferation.","evidence":"siRNA knockdown of Axin1/Axin2 in WT and Axin2-null satellite cells, β-catenin localization/reporter, β-catenin rescue, proliferation/differentiation assays","pmids":["25866367"],"confidence":"Medium","gaps":["Apparent conflict with whole-animal functional equivalence not mechanistically reconciled","Single lab"]},{"year":2017,"claim":"Distinguished AXIN2 from AXIN1 by its selective requirement for degradasome formation, and defined a Rap1b-dependent BMP/FGF integration node in skeletal stem cells.","evidence":"siRNA depletion in SW480 cells with tankyrase inhibitor and degradasome imaging; Rap1b-null mice and Axin2+ stem cell BMP/FGF analysis","pmids":["28107521","28520221"],"confidence":"Medium","gaps":["Structural determinant of AXIN2-specific degradasome nucleation unknown","Direct biochemical link between Axin2 and Rap1b not shown"]},{"year":2019,"claim":"Identified the RGS-domain aggregon as a polymerization brake whose neutralization enhances β-catenin degradation, opening a therapeutic strategy in colorectal cancer.","evidence":"Axin1/Axin2 domain swapping, aggregon point mutagenesis, polymerization and β-catenin degradation assays, peptide treatment, CRC growth assays","pmids":["31534175"],"confidence":"High","gaps":["Physiological trigger of aggregon relief not yet identified in this study","In vivo relevance of polymerization not established here"]},{"year":2019,"claim":"Demonstrated post-transcriptional silencing of AXIN2 by TGF-β-driven mRNA decay and m6A demethylation, linking AXIN2 loss to Wnt hyperactivation and immunosuppression.","evidence":"mRNA decay assays with tristetraprolin1 depletion and TβRIIΔk-fib mice; meRIP-seq with ALKBH5 knockin mice and IGF2BP1 reader analysis in CRC","pmids":["29409120","37169182"],"confidence":"High","gaps":["How multiple RNA-level controls are prioritized in a given cell type unresolved","Interaction between mRNA decay and translational 5'UTR control not integrated"]},{"year":2022,"claim":"Identified Gαi2 as a partner that induces AXIN2 condensation by targeting the RGS aggregon, providing a druggable route to suppress Wnt signaling.","evidence":"Gαi2 overexpression/knockdown, condensation and β-catenin degradation assays, Wnt reporters, guanabenz treatment, CRC mouse models","pmids":["35115535"],"confidence":"High","gaps":["Structural basis of Gαi2-aggregon engagement not resolved","Upstream signals controlling Gαi2 availability not defined"]},{"year":2023,"claim":"Expanded AXIN2's roles beyond Wnt by linking it to p53-dependent cell competition in neural progenitors and to ENO1-mediated metabolic control in neurons.","evidence":"Mosaic vs homogeneous Axin2 KO with Trp53 double KO and cortical phenotyping; Axin2/ENO1 co-interaction, XAV939 disruption, glycolysis and behavioral rescue in ASD models","pmids":["37054704","37078424"],"confidence":"High","gaps":["Mechanism by which Axin2 post-transcriptionally suppresses p53 unknown","Whether ENO1 binding is Wnt-dependent unclear","Direct biochemical AXIN2-ENO1 interface not mapped"]},{"year":null,"claim":"How AXIN2's many regulatory layers — transcriptional, translational, mRNA-decay, m6A, cell-cycle degradation, and aggregon-controlled polymerization — are integrated in vivo to select between its Wnt-scaffold, centrosomal, metabolic, and p53-suppressive functions remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model reconciling pro- and anti-tumorigenic roles","Determinants of functional partner choice (destruction complex vs C-Nap1 vs ENO1) unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,16,14,21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,4,6,14,15]}],"localization":[{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[4]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,16,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,8,10,19]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[6,4]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[13,22,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,14,15,22]}],"complexes":["β-catenin destruction complex / degradasome"],"partners":["CTNNB1","C-NAP1 (CEP250)","CDC20","GNAI2","ENO1","APC","GSK3B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y2T1","full_name":"Axin-2","aliases":["Axin-like protein","Axil","Axis inhibition protein 2","Conductin"],"length_aa":843,"mass_kda":93.6,"function":"Inhibitor of the Wnt signaling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta-catenin and APC by GSK3B","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y2T1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AXIN2","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AXIN2","total_profiled":1310},"omim":[{"mim_id":"617875","title":"POLYCYSTIC LIVER DISEASE 4 WITH OR WITHOUT KIDNEY CYSTS; PCLD4","url":"https://www.omim.org/entry/617875"},{"mim_id":"614940","title":"ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL DOMINANT; ECTD11A","url":"https://www.omim.org/entry/614940"},{"mim_id":"614659","title":"APC MEMBRANE RECRUITMENT PROTEIN 2; AMER2","url":"https://www.omim.org/entry/614659"},{"mim_id":"612752","title":"CXXC FINGER PROTEIN 5; CXXC5","url":"https://www.omim.org/entry/612752"},{"mim_id":"612034","title":"APC2 REGULATOR OF WNT SIGNALING PATHWAY 2; APC2","url":"https://www.omim.org/entry/612034"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nucleoplasm","reliability":"Uncertain"},{"location":"Plasma membrane","reliability":"Uncertain"},{"location":"Cytosol","reliability":"Uncertain"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AXIN2"},"hgnc":{"alias_symbol":["MGC126582","DKFZp781B0869"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y2T1","domains":[{"cath_id":"1.10.167.10","chopping":"75-209","consensus_level":"high","plddt":90.1457,"start":75,"end":209},{"cath_id":"2.40.240.130","chopping":"765-842","consensus_level":"high","plddt":91.3015,"start":765,"end":842}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2T1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2T1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2T1-F1-predicted_aligned_error_v6.png","plddt_mean":60.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AXIN2","jax_strain_url":"https://www.jax.org/strain/search?query=AXIN2"},"sequence":{"accession":"Q9Y2T1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y2T1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y2T1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2T1"}},"corpus_meta":[{"pmid":"11809808","id":"PMC_11809808","title":"Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11809808","citation_count":1466,"is_preprint":false},{"pmid":"15042511","id":"PMC_15042511","title":"Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.","date":"2004","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15042511","citation_count":493,"is_preprint":false},{"pmid":"12101426","id":"PMC_12101426","title":"Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12101426","citation_count":398,"is_preprint":false},{"pmid":"11940574","id":"PMC_11940574","title":"Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11940574","citation_count":319,"is_preprint":false},{"pmid":"11752446","id":"PMC_11752446","title":"Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11752446","citation_count":311,"is_preprint":false},{"pmid":"21706018","id":"PMC_21706018","title":"Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination.","date":"2011","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21706018","citation_count":289,"is_preprint":false},{"pmid":"15790973","id":"PMC_15790973","title":"The role of Axin2 in calvarial morphogenesis and craniosynostosis.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15790973","citation_count":285,"is_preprint":false},{"pmid":"30631044","id":"PMC_30631044","title":"CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30631044","citation_count":158,"is_preprint":false},{"pmid":"31866224","id":"PMC_31866224","title":"AXIN2+ Pericentral Hepatocytes Have Limited Contributions to Liver Homeostasis and Regeneration.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/31866224","citation_count":134,"is_preprint":false},{"pmid":"37169182","id":"PMC_37169182","title":"ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37169182","citation_count":127,"is_preprint":false},{"pmid":"22745173","id":"PMC_22745173","title":"Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22745173","citation_count":126,"is_preprint":false},{"pmid":"27197202","id":"PMC_27197202","title":"c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 Pathway.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27197202","citation_count":118,"is_preprint":false},{"pmid":"21626677","id":"PMC_21626677","title":"Isolated oligodontia associated with mutations in EDARADD, AXIN2, MSX1, and PAX9 genes.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21626677","citation_count":117,"is_preprint":false},{"pmid":"25236910","id":"PMC_25236910","title":"AXIN1 and AXIN2 variants in gastrointestinal cancers.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25236910","citation_count":116,"is_preprint":false},{"pmid":"15899843","id":"PMC_15899843","title":"Mouse axin and axin2/conductin proteins are functionally equivalent in vivo.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15899843","citation_count":106,"is_preprint":false},{"pmid":"26903625","id":"PMC_26903625","title":"Axin2 marks quiescent hair follicle bulge stem cells that are maintained by autocrine Wnt/β-catenin signaling.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26903625","citation_count":104,"is_preprint":false},{"pmid":"19737815","id":"PMC_19737815","title":"Axin2 controls bone remodeling through the beta-catenin-BMP signaling pathway in adult mice.","date":"2009","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19737815","citation_count":98,"is_preprint":false},{"pmid":"31883834","id":"PMC_31883834","title":"Endometrial Axin2+ Cells Drive Epithelial Homeostasis, Regeneration, and Cancer following Oncogenic Transformation.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/31883834","citation_count":96,"is_preprint":false},{"pmid":"16247484","id":"PMC_16247484","title":"Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16247484","citation_count":86,"is_preprint":false},{"pmid":"22322943","id":"PMC_22322943","title":"Cell cycle control of Wnt/β-catenin signalling by conductin/axin2 through CDC20.","date":"2012","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/22322943","citation_count":83,"is_preprint":false},{"pmid":"23589866","id":"PMC_23589866","title":"Lineage tracing with Axin2 reveals distinct developmental and adult populations of Wnt/β-catenin-responsive neural stem cells.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23589866","citation_count":80,"is_preprint":false},{"pmid":"16432638","id":"PMC_16432638","title":"Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16432638","citation_count":80,"is_preprint":false},{"pmid":"33824474","id":"PMC_33824474","title":"Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/β-catenin pathway by silencing AXIN2.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33824474","citation_count":71,"is_preprint":false},{"pmid":"21858009","id":"PMC_21858009","title":"Contrasting expression of canonical Wnt signaling reporters TOPGAL, BATGAL and Axin2(LacZ) during murine lung development and repair.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21858009","citation_count":71,"is_preprint":false},{"pmid":"21416598","id":"PMC_21416598","title":"AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21416598","citation_count":71,"is_preprint":false},{"pmid":"20300119","id":"PMC_20300119","title":"Conductin/axin2 and Wnt signalling regulates centrosome cohesion.","date":"2010","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/20300119","citation_count":69,"is_preprint":false},{"pmid":"18083923","id":"PMC_18083923","title":"Axin1 and Axin2 are regulated by TGF- and mediate cross-talk between TGF- and Wnt signaling pathways.","date":"2007","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18083923","citation_count":66,"is_preprint":false},{"pmid":"10049590","id":"PMC_10049590","title":"Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10049590","citation_count":63,"is_preprint":false},{"pmid":"31814849","id":"PMC_31814849","title":"miR-221-3p and miR-15b-5p promote cell proliferation and invasion by targeting Axin2 in liver cancer.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31814849","citation_count":60,"is_preprint":false},{"pmid":"29534875","id":"PMC_29534875","title":"Esculetin suppresses tumor growth and metastasis by targeting Axin2/E-cadherin axis in colorectal cancer.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29534875","citation_count":57,"is_preprint":false},{"pmid":"31454276","id":"PMC_31454276","title":"Axin2+-Mesenchymal PDL Cells, Instead of K14+ Epithelial Cells, Play a Key Role in Rapid Cementum Growth.","date":"2019","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/31454276","citation_count":57,"is_preprint":false},{"pmid":"18790474","id":"PMC_18790474","title":"Axis inhibition protein 2 (AXIN2) polymorphisms and tooth agenesis.","date":"2008","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/18790474","citation_count":55,"is_preprint":false},{"pmid":"28069701","id":"PMC_28069701","title":"Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/28069701","citation_count":54,"is_preprint":false},{"pmid":"25866367","id":"PMC_25866367","title":"Coordinated action of Axin1 and Axin2 suppresses β-catenin to regulate muscle stem cell function.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25866367","citation_count":51,"is_preprint":false},{"pmid":"27578179","id":"PMC_27578179","title":"Wnt/β-catenin signaling via Axin2 is required for myogenesis and, together with YAP/Taz and Tead1, active in IIa/IIx muscle fibers.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27578179","citation_count":50,"is_preprint":false},{"pmid":"21555575","id":"PMC_21555575","title":"Tissue-specific roles of Axin2 in the inhibition and activation of Wnt signaling in the mouse embryo.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21555575","citation_count":49,"is_preprint":false},{"pmid":"28694128","id":"PMC_28694128","title":"MicroRNA-221-3p promotes pulmonary artery smooth muscle cells proliferation by targeting AXIN2 during pulmonary arterial hypertension.","date":"2017","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28694128","citation_count":48,"is_preprint":false},{"pmid":"17373666","id":"PMC_17373666","title":"Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17373666","citation_count":47,"is_preprint":false},{"pmid":"30471109","id":"PMC_30471109","title":"LncRNA miR143HG suppresses bladder cancer development through inactivating Wnt/β-catenin pathway by modulating miR-1275/AXIN2 axis.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30471109","citation_count":46,"is_preprint":false},{"pmid":"18755497","id":"PMC_18755497","title":"Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability.","date":"2008","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18755497","citation_count":45,"is_preprint":false},{"pmid":"34401997","id":"PMC_34401997","title":"Zeb2/Axin2-Enriched BMSC-Derived Exosomes Promote Post-Stroke Functional Recovery by Enhancing Neurogenesis and Neural Plasticity.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/34401997","citation_count":44,"is_preprint":false},{"pmid":"23393221","id":"PMC_23393221","title":"Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23393221","citation_count":43,"is_preprint":false},{"pmid":"31273221","id":"PMC_31273221","title":"miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31273221","citation_count":43,"is_preprint":false},{"pmid":"18372914","id":"PMC_18372914","title":"Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18372914","citation_count":43,"is_preprint":false},{"pmid":"23838596","id":"PMC_23838596","title":"A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23838596","citation_count":43,"is_preprint":false},{"pmid":"31534175","id":"PMC_31534175","title":"An aggregon in conductin/axin2 regulates Wnt/β-catenin signaling and holds potential for cancer therapy.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31534175","citation_count":41,"is_preprint":false},{"pmid":"35115535","id":"PMC_35115535","title":"Gαi2-induced conductin/axin2 condensates inhibit Wnt/β-catenin signaling and suppress cancer growth.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35115535","citation_count":39,"is_preprint":false},{"pmid":"19623616","id":"PMC_19623616","title":"Axin2 regulates chondrocyte maturation and axial skeletal development.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/19623616","citation_count":39,"is_preprint":false},{"pmid":"26191213","id":"PMC_26191213","title":"miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26191213","citation_count":39,"is_preprint":false},{"pmid":"32064157","id":"PMC_32064157","title":"TFRC promotes epithelial ovarian cancer cell proliferation and metastasis via up-regulation of AXIN2 expression.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32064157","citation_count":38,"is_preprint":false},{"pmid":"28107521","id":"PMC_28107521","title":"Differential Roles of AXIN1 and AXIN2 in Tankyrase Inhibitor-Induced Formation of Degradasomes and β-Catenin Degradation.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28107521","citation_count":37,"is_preprint":false},{"pmid":"15538750","id":"PMC_15538750","title":"Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15538750","citation_count":36,"is_preprint":false},{"pmid":"27853243","id":"PMC_27853243","title":"Axin2-expressing cells execute regeneration after skeletal injury.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27853243","citation_count":35,"is_preprint":false},{"pmid":"24581859","id":"PMC_24581859","title":"Novel missense mutations in the AXIN2 gene associated with non-syndromic oligodontia.","date":"2013","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/24581859","citation_count":35,"is_preprint":false},{"pmid":"23300083","id":"PMC_23300083","title":"Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23300083","citation_count":34,"is_preprint":false},{"pmid":"29409120","id":"PMC_29409120","title":"Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2.","date":"2018","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/29409120","citation_count":34,"is_preprint":false},{"pmid":"25504512","id":"PMC_25504512","title":"The roles of AXIN2 in tumorigenesis and epigenetic regulation.","date":"2015","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25504512","citation_count":33,"is_preprint":false},{"pmid":"16941501","id":"PMC_16941501","title":"Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16941501","citation_count":33,"is_preprint":false},{"pmid":"35001706","id":"PMC_35001706","title":"Axin2+ PDL Cells Directly Contribute to New Alveolar Bone Formation in Response to Orthodontic Tension Force.","date":"2022","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/35001706","citation_count":32,"is_preprint":false},{"pmid":"21530942","id":"PMC_21530942","title":"Sequence analysis of PAX9, MSX1 and AXIN2 genes in a Chinese oligodontia family.","date":"2011","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/21530942","citation_count":32,"is_preprint":false},{"pmid":"11474173","id":"PMC_11474173","title":"Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11474173","citation_count":30,"is_preprint":false},{"pmid":"33574925","id":"PMC_33574925","title":"Curcumin suppresses colorectal tumorigenesis via the Wnt/β-catenin signaling pathway by downregulating Axin2.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33574925","citation_count":30,"is_preprint":false},{"pmid":"33811251","id":"PMC_33811251","title":"Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33811251","citation_count":29,"is_preprint":false},{"pmid":"28783177","id":"PMC_28783177","title":"Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28783177","citation_count":29,"is_preprint":false},{"pmid":"27188720","id":"PMC_27188720","title":"SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: both expressed at low levels in breast cancer.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27188720","citation_count":29,"is_preprint":false},{"pmid":"28939076","id":"PMC_28939076","title":"Snail and Axin2 expression predict the malignant transformation of oral leukoplakia.","date":"2017","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28939076","citation_count":28,"is_preprint":false},{"pmid":"28520221","id":"PMC_28520221","title":"Rap1b Is an Effector of Axin2 Regulating Crosstalk of Signaling Pathways During Skeletal Development.","date":"2017","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/28520221","citation_count":28,"is_preprint":false},{"pmid":"23936395","id":"PMC_23936395","title":"Absence of endochondral ossification and craniosynostosis in posterior frontal cranial sutures of Axin2(-/-) mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23936395","citation_count":28,"is_preprint":false},{"pmid":"15885887","id":"PMC_15885887","title":"Regulation of axin2 expression at the levels of transcription, translation and protein stability in lung and colon cancer.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15885887","citation_count":27,"is_preprint":false},{"pmid":"24964857","id":"PMC_24964857","title":"DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24964857","citation_count":26,"is_preprint":false},{"pmid":"34706645","id":"PMC_34706645","title":"circ_0038718 promotes colon cancer cell malignant progression via the miR-195-5p/Axin2 signaling axis and also effect Wnt/β-catenin signal pathway.","date":"2021","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34706645","citation_count":26,"is_preprint":false},{"pmid":"22370446","id":"PMC_22370446","title":"Association of AXIN2 with non-syndromic oral clefts in multiple populations.","date":"2012","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/22370446","citation_count":26,"is_preprint":false},{"pmid":"25091576","id":"PMC_25091576","title":"The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25091576","citation_count":26,"is_preprint":false},{"pmid":"30279163","id":"PMC_30279163","title":"Pygo2 Regulates Adiposity and Glucose Homeostasis via β-Catenin-Axin2-GSK3β Signaling Pathway.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30279163","citation_count":25,"is_preprint":false},{"pmid":"32575385","id":"PMC_32575385","title":"GLI1 and AXIN2 Are Distinctive Markers of Human Calvarial Mesenchymal Stromal Cells in Nonsyndromic Craniosynostosis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32575385","citation_count":25,"is_preprint":false},{"pmid":"27144473","id":"PMC_27144473","title":"Barx2 and Pax7 Regulate Axin2 Expression in Myoblasts by Interaction with β-Catenin and Chromatin Remodelling.","date":"2016","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/27144473","citation_count":24,"is_preprint":false},{"pmid":"15611123","id":"PMC_15611123","title":"Expression of axin2 is regulated by the alternative 5'-untranslated regions of its mRNA.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15611123","citation_count":24,"is_preprint":false},{"pmid":"27701636","id":"PMC_27701636","title":"Loss of Axin2 Causes Ocular Defects During Mouse Eye Development.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27701636","citation_count":24,"is_preprint":false},{"pmid":"36155281","id":"PMC_36155281","title":"Hederagenin ameliorates cisplatin-induced acute kidney injury via inhibiting long non-coding RNA A330074k22Rik/Axin2/β-catenin signalling pathway.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36155281","citation_count":23,"is_preprint":false},{"pmid":"22887353","id":"PMC_22887353","title":"Association of DVL2 and AXIN2 gene polymorphisms with cleft lip with or without cleft palate in a Polish population.","date":"2012","source":"Birth defects research. Part A, Clinical and molecular teratology","url":"https://pubmed.ncbi.nlm.nih.gov/22887353","citation_count":23,"is_preprint":false},{"pmid":"30671715","id":"PMC_30671715","title":"Phenotypic confirmation of oligodontia, colorectal polyposis and cancer in a family carrying an exon 7 nonsense variant in the AXIN2 gene.","date":"2019","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30671715","citation_count":23,"is_preprint":false},{"pmid":"30070321","id":"PMC_30070321","title":"MiR-183 maintains canonical Wnt signaling activity and regulates growth and apoptosis in bladder cancer via targeting AXIN2.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30070321","citation_count":22,"is_preprint":false},{"pmid":"33465373","id":"PMC_33465373","title":"Axin2+ Peribiliary Glands in the Periampullary Region Generate Biliary Epithelial Stem Cells That Give Rise to Ampullary Carcinoma.","date":"2021","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/33465373","citation_count":22,"is_preprint":false},{"pmid":"37488774","id":"PMC_37488774","title":"Pancreatic stellate cell-derived exosomal tRF-19-PNR8YPJZ promotes proliferation and mobility of pancreatic cancer through AXIN2.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37488774","citation_count":21,"is_preprint":false},{"pmid":"29307822","id":"PMC_29307822","title":"miR-3120-5p promotes colon cancer stem cell stemness and invasiveness through targeting Axin2.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29307822","citation_count":21,"is_preprint":false},{"pmid":"35197279","id":"PMC_35197279","title":"The nonredundant nature of the Axin2 regulatory network in the canonical Wnt signaling pathway.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35197279","citation_count":21,"is_preprint":false},{"pmid":"26406231","id":"PMC_26406231","title":"A Novel AXIN2 Missense Mutation Is Associated with Non-Syndromic Oligodontia.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26406231","citation_count":21,"is_preprint":false},{"pmid":"28759178","id":"PMC_28759178","title":"Mutations in AXIN2 gene as a risk factor for tooth agenesis and cancer: A review.","date":"2017","source":"Neuro endocrinology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28759178","citation_count":20,"is_preprint":false},{"pmid":"21069480","id":"PMC_21069480","title":"AXIN2 polymorphism and its association with prostate cancer in a Turkish population.","date":"2010","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21069480","citation_count":20,"is_preprint":false},{"pmid":"34093820","id":"PMC_34093820","title":"MicroRNA-1246 by Targeting AXIN2 and GSK-3β Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34093820","citation_count":19,"is_preprint":false},{"pmid":"26617789","id":"PMC_26617789","title":"MiR-374a promotes the proliferation of osteosarcoma cell proliferation by targeting Axin2.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617789","citation_count":19,"is_preprint":false},{"pmid":"37054704","id":"PMC_37054704","title":"Stem cell competition driven by the Axin2-p53 axis controls brain size during murine development.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/37054704","citation_count":18,"is_preprint":false},{"pmid":"36331809","id":"PMC_36331809","title":"LncRNA GAS5 regulates the Wnt/β-catenin pathway through the miR-18a-5p/AXIN2/GSK3β axis to inhibit the proliferation and migration of bladder cancer cells.","date":"2022","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36331809","citation_count":18,"is_preprint":false},{"pmid":"21733995","id":"PMC_21733995","title":"Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21733995","citation_count":18,"is_preprint":false},{"pmid":"37078424","id":"PMC_37078424","title":"Axin2 coupled excessive Wnt-glycolysis signaling mediates social defect in autism spectrum disorders.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37078424","citation_count":17,"is_preprint":false},{"pmid":"26252180","id":"PMC_26252180","title":"MicroRNA-374a promotes esophageal cancer cell proliferation via Axin2 suppression.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26252180","citation_count":17,"is_preprint":false},{"pmid":"18563716","id":"PMC_18563716","title":"Axin2 expression identifies progenitor cells in the murine prostate.","date":"2008","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/18563716","citation_count":17,"is_preprint":false},{"pmid":"34817745","id":"PMC_34817745","title":"Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer.","date":"2021","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34817745","citation_count":16,"is_preprint":false},{"pmid":"24222224","id":"PMC_24222224","title":"Mutational analysis of AXIN2, MSX1, and PAX9 in two Mexican oligodontia families.","date":"2013","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24222224","citation_count":16,"is_preprint":false},{"pmid":"33046030","id":"PMC_33046030","title":"The Axin2-snail axis promotes bone invasion by activating cancer-associated fibroblasts in oral squamous cell carcinoma.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33046030","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50720,"output_tokens":7454,"usd":0.131985,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16937,"output_tokens":5819,"usd":0.11508,"stage2_stop_reason":"end_turn"},"total_usd":0.247065,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Axin2 is a direct transcriptional target of the Wnt/β-catenin pathway, activated through TCF/LEF binding sites in its promoter and first intron. Mutation or deletion of TCF/LEF sites greatly diminished induction by β-catenin, and mutation of site T2 abolished protein binding in an EMSA. This establishes Axin2 as part of a negative feedback loop that limits Wnt signal duration/intensity.\",\n      \"method\": \"Reporter constructs with 5.6-kb genomic fragment, TCF/LEF site mutagenesis, EMSA, transgenic embryo analysis, endogenous mRNA/protein induction assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (EMSA, mutagenesis, reporter assays, transgenic validation) in a single rigorous study, replicated by independent lab (PMID:11940574)\",\n      \"pmids\": [\"11809808\", \"11940574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"AXIN2 expression is strongly induced by activated β-catenin-TCF signaling via TCF binding sites in the AXIN2 promoter; dominant-negative TCF-4 represses AXIN2 expression. Restoration of wild-type APC suppresses AXIN2. This positions AXIN2 in a negative feedback pathway regulating Wnt signaling, distinct from AXIN1 which is not regulated by β-catenin-TCF.\",\n      \"method\": \"β-catenin-estrogen receptor fusion activation, Wnt1 overexpression, dominant-negative TCF-4, APC restoration, TCF binding site reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (inducible β-catenin, Wnt1, dnTCF-4, APC restoration, reporter assays), independently replicated (PMID:11809808)\",\n      \"pmids\": [\"11940574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Axin2 and Axin1 proteins are functionally equivalent in vivo. Knockin mice expressing Axin2 cDNA under the Axin1 locus (Axin^Ax2/Ax2) are apparently normal and fertile, demonstrating that the lack of redundancy between the two proteins in wild-type animals is due to their different expression patterns rather than different protein functions.\",\n      \"method\": \"Knockin mouse generation (Axin cDNA replaced with Axin2 cDNA), viability and fertility assessment of homozygous knockin mice\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean in vivo genetic rescue with defined phenotypic readout (viability/fertility), robust experimental design\",\n      \"pmids\": [\"15899843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Axin2 is expressed at osteogenic fronts and periosteum of developing sutures; targeted disruption of Axin2 in mice causes craniosynostosis through enhanced β-catenin signaling, increased osteoprogenitor expansion, accelerated ossification, and stimulated osteoblast proliferation and differentiation. The craniofacial anomalies are mediated through activation of β-catenin signaling.\",\n      \"method\": \"Axin2 knockout mice, in vivo/in vitro osteoblast differentiation assays, β-catenin signaling analysis, osteogenic marker expression\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined mechanistic pathway (β-catenin activation), multiple cellular phenotype readouts, in vitro validation\",\n      \"pmids\": [\"15790973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Conductin/Axin2 localizes at centrosomes by binding to the centriole-associated component C-Nap1. Knockout or knockdown of conductin leads to premature centrosome separation (splitting), which is abolished by knockdown of β-catenin. Conductin promotes phosphorylation of N-terminal serine/threonine residues (Ser33/37, Thr41) of centrosome-associated β-catenin; β-catenin mutated at these residues causes centrosomal splitting. Treatment with Wnts and GSK3 inhibition block β-catenin phosphorylation and induce centrosomal splitting.\",\n      \"method\": \"Conductin KO/KD, β-catenin KD, centrosome localization imaging, phospho-β-catenin mutant analysis, Wnt/GSK3 inhibitor treatment\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal KO/KD with mechanistic follow-up (phospho-mutants, C-Nap1 binding), multiple orthogonal methods\",\n      \"pmids\": [\"20300119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Axin2 function is essential for normal kinetics of oligodendrocyte progenitor cell (OLP) differentiation and remyelination after injury. The small molecule tankyrase inhibitor XAV939 stabilizes Axin2 levels in OLPs and accelerates their differentiation and myelination after hypoxic and demyelinating injury.\",\n      \"method\": \"Axin2 loss-of-function in vivo, XAV939 (tankyrase inhibitor) treatment of OLPs from brain and spinal cord, remyelination assays after hypoxic/demyelinating injury\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined remyelination phenotype plus pharmacological rescue with mechanistic basis (Axin2 stabilization via tankyrase inhibition)\",\n      \"pmids\": [\"21706018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Conductin/Axin2 levels peak at G2/M and are rapidly degraded during return to G1. Conductin is degraded by the APC/C cofactor CDC20. CDC20 knockdown blocks Wnt signaling through conductin. CDC20-resistant conductin inhibits Wnt signaling and attenuates colony formation. β-catenin phosphorylation oscillates during the cell cycle in a conductin-dependent manner.\",\n      \"method\": \"Cell cycle synchronization, CDC20 knockdown, CDC20-resistant conductin mutant expression, Wnt signaling reporters, colony formation assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — identified specific E3 ligase component (CDC20/APC-C) as conductin writer/eraser, validated with resistant mutant and KD, multiple readouts\",\n      \"pmids\": [\"22322943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Axin2 promotes colon carcinoma oncogenic activity (rather than acting as a tumor suppressor) by upregulating the transcriptional repressor Snail1, inducing epithelial-mesenchymal transition (EMT) and driving metastatic activity. Silencing Axin2 decreases Snail1 activity, reverses EMT, and inhibits CRC invasive and metastatic activities.\",\n      \"method\": \"Axin2 silencing in CRC cells, Snail1 activity assays, EMT marker analysis, invasion and metastasis assays in vitro and in vivo, Wnt-regulated transcriptome analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined molecular pathway (Axin2→Snail1→EMT), multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"22745173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Axin2 is a key negative regulator of bone remodeling in adult mice; its loss increases trabecular bone mass and bone formation rates, and increases nuclear β-catenin in BMS cells. Axin2 KO-enhanced osteoblast differentiation is reversed by β-catenin deletion. Axin2 regulates osteoblast differentiation through the β-catenin-BMP2/4-Osterix signaling pathway.\",\n      \"method\": \"Axin2 KO mice, bone marrow stromal cell isolation, in vitro β-catenin deletion rescue, BMP2/4 mRNA and pSmad1/5 analysis, GSK3β inhibitor BIO treatment, Bmp2/4 conditional deletion\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with defined bone phenotype, genetic rescue (β-catenin deletion), BMP2/4 pathway downstream validation, pharmacological confirmation\",\n      \"pmids\": [\"19737815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The Axin2(canp) V26D substitution in an N-terminal sequence motif results in a more stable Axin2 protein. Increased stability of Axin2 generally decreases Wnt signaling in most tissues but paradoxically enhances canonical Wnt activity in the late primitive streak. Treatment of wild-type embryos with a tankyrase inhibitor that stabilizes Axin proteins phenocopies this, confirming that Axin2 stability is a key regulatory mechanism.\",\n      \"method\": \"ENU-induced Axin2(canp) allele characterization, protein stability assays, tissue-specific Wnt signaling reporter analysis, tankyrase inhibitor treatment of embryos\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single lab, allelic characterization plus pharmacological validation, but mechanistic basis of tissue-specific paradoxical activation not fully resolved\",\n      \"pmids\": [\"21555575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Axin2 functions upstream of Rap1b in skeletal development: Axin2 regulates Rap1b through modulation of canonical BMP signaling. Rap1b acts as a signaling integrator for FGF and BMP downstream of Axin2; BMP-mediated activation of Rap1b promotes chondrogenic fate and inhibits MAPK/FGF-driven osteoblast differentiation.\",\n      \"method\": \"Genetic analysis of Rap1b-null mice, Axin2+ stem cell characterization, BMP/FGF signaling pathway analysis, osteogenic/chondrogenic differentiation assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined epistatic relationship (Axin2→BMP→Rap1b) with genetic KO validation, single lab\",\n      \"pmids\": [\"28520221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Runx2 represses Axin2 transcription via Hdac3, by binding to multiple regions of the Axin2 promoter. Runx2 haploinsufficiency in Axin2-null mice rescues the craniosynostosis phenotype, placing Runx2 upstream of Axin2 in a pathway regulating intramembranous bone development.\",\n      \"method\": \"ChIP (Runx2 binding to Axin2 promoter), Hdac3-dependent repression assays, Axin2(-/-):Runx2(+/-) double mutant mice, skull morphology analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP identifying direct promoter binding, genetic epistasis via double-mutant rescue, Hdac3 functional dependency established\",\n      \"pmids\": [\"23300083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In satellite cells (muscle stem cells), Axin1 and Axin2 have non-equivalent functions: Axin1 knockdown in Axin2-null cells strongly inhibits proliferation, induces differentiation, causes nuclear β-catenin localization, and activates TCF reporter activity. These effects are rescued by concomitant β-catenin knockdown, demonstrating that Axin1 and Axin2 cooperate to suppress β-catenin signaling and maintain myoblast proliferation.\",\n      \"method\": \"siRNA knockdown of Axin1 and Axin2 in WT and Axin2-null satellite cells, β-catenin localization/reporter assays, retroviral Axin2 overexpression, proliferation/differentiation assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (double KD + β-catenin rescue), Axin2-null cells, TCF reporter, single lab\",\n      \"pmids\": [\"25866367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Axin2 mRNA contains alternative 5'-untranslated regions (5'UTRs) that differentially regulate translational efficiency via short upstream reading frames and structural motifs. Proportional expression of each 5'UTR variant influences total Axin2 protein levels, establishing a translational control mechanism for Axin2 expression.\",\n      \"method\": \"5'UTR reporter constructs, mRNA stability assays, translational efficiency measurements, characterization of upstream ORFs and secondary structures\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro/cell-based mechanistic dissection of 5'UTR regulatory elements, single lab with multiple readouts\",\n      \"pmids\": [\"15611123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"An aggregation site (aggregon) in the RGS domain of conductin/Axin2 prevents its polymerization and limits its activity relative to Axin1. Point mutations that neutralize this aggregon enhance conductin polymerization and β-catenin degradation. A short peptide that masks the aggregon induces conductin polymerization, enhances β-catenin degradation, inhibits β-catenin-dependent transcription, and represses colorectal cancer cell growth.\",\n      \"method\": \"Domain swapping between Axin1 and Axin2, point mutagenesis of aggregon, polymerization assays, β-catenin degradation assays, Wnt reporter assays, colorectal cancer cell growth assays, peptide treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain swapping, mutagenesis, reconstitution of polymerization, multiple functional readouts (β-catenin degradation, transcription, cell growth)\",\n      \"pmids\": [\"31534175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Gαi2 induces conductin/Axin2 condensation by targeting the polymerization-inhibiting aggregon in its RGS domain, thereby promoting conductin-mediated β-catenin degradation and inhibiting Wnt signaling. Transient Gαi2 expression inhibits Wnt signaling, Gαi2 knockdown activates it, and the Gαi2-activating drug guanabenz inhibits Wnt signaling via conductin, reducing colorectal cancer growth in vitro and in mouse models.\",\n      \"method\": \"Gαi2 overexpression/knockdown, conductin condensation assays, β-catenin degradation assays, Wnt reporter assays, guanabenz drug treatment, colorectal cancer mouse models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — identification of Gαi2 as a conductin binding partner/activator with mechanistic follow-up (aggregon targeting, condensate formation), in vitro + in vivo validation\",\n      \"pmids\": [\"35115535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AXIN2 is required for degradasome formation and β-catenin degradation upon tankyrase inhibition in SW480 cells. AXIN1 is not required for degradasome formation, whereas depletion of AXIN2 considerably impairs both degradasome formation and their capacity to degrade β-catenin. This reveals a differential and non-redundant role for AXIN2 (vs AXIN1) in the β-catenin destruction complex.\",\n      \"method\": \"siRNA depletion of AXIN1 and AXIN2 in SW480 cells, tankyrase inhibitor G007-LK treatment, degradasome imaging, β-catenin degradation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single lab, reciprocal depletion with defined cellular phenotype, functional readout (β-catenin degradation)\",\n      \"pmids\": [\"28107521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TGF-β suppresses the expression of both Axin1 and Axin2 in chondrocytes through a Smad3-dependent mechanism. In Axin2(-/-) chondrocytes, TGF-β treatment results in a sustained increase in β-catenin levels compared to wild-type. Overexpression of Axin2 enhances TGF-β signaling while overexpression of β-catenin inhibits Smad3-sensitive reporters, demonstrating that Axin2 mediates cross-talk between TGF-β and Wnt/β-catenin signaling pathways.\",\n      \"method\": \"Axin2(-/-) and Smad3(-/-) chondrocytes, TGF-β treatment, Smad3-sensitive reporter assays, β-catenin measurement, Axin overexpression\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO cells with defined pathway cross-talk, Smad3 genetic dependency, single lab\",\n      \"pmids\": [\"18083923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Epigenetic silencing of AXIN2 through TGF-β-dependent increase in AXIN2 mRNA decay reduces Axin2 protein levels in systemic sclerosis fibroblasts, causing sensitization to canonical Wnt ligands. XAV939-mediated stabilization of Axin2 (via tankyrase inhibition) reverses the increased Wnt response, demonstrating that reduced Axin2 bioavailability is the mechanistic basis for TGF-β-primed Wnt activation.\",\n      \"method\": \"TGF-β treatment of fibroblasts, Axin2 mRNA decay assays, TGFβRI blockade, siRNA-mediated tristetraprolin1 depletion, XAV939 treatment, TOPflash reporter assays, Axin2 gain/loss-of-function\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA decay mechanism identified, in vivo TβRIIΔk-fib transgenic mouse validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"29409120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Axin2 suppresses the p53 signaling pathway at the post-transcriptional level to maintain neural progenitor cell (NPC) fitness. In a mosaic setting, Axin2-deficient NPCs behave as 'losers' and undergo p53-dependent apoptotic elimination via cell competition. Homogeneous Axin2 ablation does not promote cell death. Conditional loss of both Axin2 and Trp53 increases cortical area and thickness.\",\n      \"method\": \"Mosaic genetic mosaicism induction, Axin2-conditional KO, p53/Trp53 conditional KO, double conditional KO, NPC apoptosis quantification, cortical size measurement\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mosaic vs. homogeneous KO distinguishes cell competition mechanism, genetic double KO epistasis, defined cellular and developmental phenotype\",\n      \"pmids\": [\"37054704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Axin2 interacts with the glycolytic enzyme enolase 1 (ENO1) in ASD neurons. An Axin2 stabilizer (XAV939) blocked the Axin2/ENO1 interaction, switched glycolysis/oxidative phosphorylation balance, promoted synaptic maturation, and rescued social function in ASD mouse models.\",\n      \"method\": \"Co-interaction assays for Axin2/ENO1, XAV939 treatment, glycolysis measurement, synaptic maturation assays, behavioral testing in Shank3(-/-) and VPA-treated mice\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel binding partner identified (ENO1), pharmacological disruption with functional readout, in vivo behavioral rescue, single lab\",\n      \"pmids\": [\"37078424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Overexpression of wild-type AXIN2 inhibits Wnt-3a-stimulated TCF/LEF-dependent transcription in medulloblastoma cells. In contrast, an AXIN2 mutant with a deleted C-terminal DIX domain activates the Wnt signaling pathway, demonstrating that the DIX domain is required for Axin2's inhibitory function on Wnt signaling.\",\n      \"method\": \"Wild-type and DIX-domain-deleted AXIN2 overexpression in MB cell lines, luciferase Wnt reporter assays, Wnt-3a stimulation\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — domain deletion mutagenesis with functional reporter readout, single lab\",\n      \"pmids\": [\"17373666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALKBH5, an RNA N6-methyladenosine (m6A) eraser, binds and demethylates AXIN2 mRNA, causing its dissociation from the m6A reader IGF2BP1 and subsequent degradation. Loss of AXIN2 mRNA stability results in hyperactivated Wnt/β-catenin signaling, increased DKK1, and MDSC-driven immunosuppression in colorectal cancer.\",\n      \"method\": \"Methylated RNA immunoprecipitation sequencing, RNA sequencing, ALKBH5 knockin mice, allografts, CD34+ humanized mice, flow cytometry, in vitro/in vivo functional assays\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — meRIP-seq identifies AXIN2 as ALKBH5 substrate, IGF2BP1 reader mechanism characterized, multiple in vivo models validate functional consequence\",\n      \"pmids\": [\"37169182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDX2 transcriptionally activates AXIN2 expression by directly binding to an upstream enhancer of AXIN2, as confirmed by dual-luciferase reporter and quantitative ChIP assays. CDX2 knockdown reduces AXIN2 expression and enhances Wnt/β-catenin signaling, while CDX2 overexpression increases AXIN2 and suppresses Wnt signaling.\",\n      \"method\": \"Dual-luciferase reporter assay, quantitative ChIP, CDX2 knockdown/overexpression, Wnt pathway activity assays (TOP/FOP-Flash), β-catenin target gene expression\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — qChIP identifies direct CDX2 binding to AXIN2 enhancer, functional reporter validation, single lab\",\n      \"pmids\": [\"30631044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDX2 activates AXIN2 promoter activity via intestinal cell-specific enhancer elements, as shown by transfection of intestinal and non-intestinal cell lines. Suppressed CDX2 is associated with endogenous downregulation of AXIN2 expression in Caco-2 cells, confirming CDX2 as a transcriptional activator of AXIN2.\",\n      \"method\": \"Promoter-enhancer reporter transfection assays, CDX2 knockdown, endogenous AXIN2 mRNA quantification\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — reporter assays plus endogenous expression validation, replicated by PMID:30631044, single method per study\",\n      \"pmids\": [\"23393221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TGF-β activation decreases Axin2 expression in fibroblasts through a TGF-β-dependent increase in Axin2 mRNA decay, mediated by tristetraprolin 1. This reduction in Axin2 bioavailability is necessary for TGF-β to prime canonical Wnt signaling. In vivo validation in TβRIIΔk-fib transgenic mice confirms decreased Axin2 mRNA and protein in fibroblasts with dysregulated TGF-β signaling.\",\n      \"method\": \"mRNA decay assays, siRNA knockdown of tristetraprolin 1, TGFβRI blockade, Axin2 gain/loss-of-function, TOPflash assay, TβRIIΔk-fib transgenic mouse analysis\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic identification of mRNA decay pathway, in vivo transgenic mouse confirmation, single lab\",\n      \"pmids\": [\"29409120\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AXIN2 (conductin/Axil) is a scaffold protein and direct transcriptional target of the Wnt/β-catenin-TCF/LEF pathway that functions in a negative feedback loop: upon Wnt activation, β-catenin-TCF drives AXIN2 transcription, and the resulting AXIN2 protein joins the β-catenin destruction complex (with APC, GSK-3β, CK1) to promote β-catenin phosphorylation and proteasomal degradation; AXIN2 protein levels are further regulated post-translationally by CDC20/APC-C-mediated degradation at G2/M, by tankyrase-mediated ubiquitination, and by a polymerization-inhibiting aggregon in its RGS domain that is relieved by Gαi2 binding; AXIN2 also localizes to centrosomes via C-Nap1 to regulate β-catenin phosphorylation and centrosome cohesion, interacts with ENO1 to modulate glycolysis/oxidative phosphorylation balance, suppresses p53 signaling post-transcriptionally to maintain cell fitness during neural progenitor cell competition, and acts through Rap1b to integrate BMP and FGF cross-talk in skeletal development; additionally, in certain cancer contexts AXIN2 promotes EMT and metastasis by upregulating Snail1, revealing context-dependent pro- and anti-tumorigenic roles.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AXIN2 (conductin/Axil) is a scaffold protein that operates as the central node of a negative feedback loop in Wnt/\\u03b2-catenin signaling: it is itself a direct transcriptional target of \\u03b2-catenin-TCF/LEF, induced through TCF/LEF sites in its promoter and first intron, and the resulting protein joins the \\u03b2-catenin destruction complex to drive \\u03b2-catenin N-terminal phosphorylation (Ser33/37, Thr41) and degradation, thereby limiting Wnt signal duration [#0, #1, #4]. AXIN2 and AXIN1 are functionally interchangeable proteins whose distinct biology derives from differing expression rather than intrinsic function [#2], yet AXIN2 has non-redundant, context-specific roles \\u2014 it is selectively required for degradasome formation upon tankyrase inhibition [#16] and cooperates with AXIN1 to restrain \\u03b2-catenin in stem cell pools [#12]; its inhibitory activity depends on the C-terminal DIX domain [#21]. AXIN2 activity is tightly tuned at multiple post-transcriptional levels: a polymerization-inhibiting aggregon in its RGS domain limits its assembly and \\u03b2-catenin-degrading capacity, a constraint relieved by G\\u03b1i2-induced condensation [#14, #15]; its protein level oscillates across the cell cycle through APC/C-CDC20-mediated degradation at the G2/M-to-G1 transition [#6]; and its stability and mRNA abundance are controlled by tankyrase, alternative 5'UTRs, and TGF-\\u03b2-driven mRNA decay and m6A-dependent turnover [#9, #13, #18, #22]. Through this circuitry AXIN2 governs skeletal development and bone remodeling \\u2014 its loss causes craniosynostosis and increased bone mass via \\u03b2-catenin-BMP2/4-Osterix signaling and a Rap1b-integrated BMP/FGF axis \\u2014 and is itself transcriptionally controlled by Runx2 and CDX2 [#3, #8, #10, #11, #23]. Beyond canonical Wnt regulation, AXIN2 localizes to centrosomes via C-Nap1 to maintain centrosome cohesion [#4], suppresses p53 signaling post-transcriptionally to sustain neural progenitor fitness during cell competition [#19], and interacts with the glycolytic enzyme ENO1 to modulate glycolysis/oxidative phosphorylation balance [#20]. In cancer it shows context-dependent roles, acting as a tumor suppressor whose enforced polymerization restrains colorectal cancer growth [#14, #15] yet, in other contexts, promoting EMT and metastasis by upregulating Snail1 [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that AXIN2 is a direct \\u03b2-catenin-TCF transcriptional target, defining the negative feedback architecture that distinguishes it from AXIN1.\",\n      \"evidence\": \"Reporter constructs, TCF/LEF site mutagenesis, EMSA, transgenic embryos, and inducible \\u03b2-catenin/Wnt1/dnTCF-4 perturbation\",\n      \"pmids\": [\"11809808\", \"11940574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how AXIN2 protein engages the destruction complex\", \"Does not resolve tissue-specific differences in feedback strength\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed AXIN2 and AXIN1 proteins are functionally equivalent in vivo, attributing their non-redundancy to expression patterns rather than protein function.\",\n      \"evidence\": \"Knockin mice expressing Axin2 cDNA from the Axin1 locus, scored for viability and fertility\",\n      \"pmids\": [\"15899843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whole-organism rescue does not exclude cell-type-specific functional differences later observed in stem cells and degradasomes\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked AXIN2 to skeletal development, showing its loss causes craniosynostosis via enhanced \\u03b2-catenin-driven osteoprogenitor expansion.\",\n      \"evidence\": \"Axin2 knockout mice with osteoblast differentiation and \\u03b2-catenin signaling readouts\",\n      \"pmids\": [\"15790973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define upstream transcriptional control of Axin2 in sutures\", \"Downstream osteogenic effectors not yet mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended AXIN2's skeletal role to adult bone remodeling and identified the \\u03b2-catenin-BMP2/4-Osterix axis as the effector pathway.\",\n      \"evidence\": \"Axin2 KO mice, BMS cell differentiation, \\u03b2-catenin deletion rescue, BMP2/4 conditional deletion, GSK3\\u03b2 inhibitor treatment\",\n      \"pmids\": [\"19737815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish whether BMP2/4 induction is direct or secondary to \\u03b2-catenin\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified a non-canonical centrosomal role: AXIN2 binds C-Nap1 and locally phosphorylates \\u03b2-catenin to maintain centrosome cohesion.\",\n      \"evidence\": \"Conductin KO/KD, \\u03b2-catenin KD, centrosome imaging, phospho-mutant \\u03b2-catenin analysis, Wnt/GSK3 inhibitor treatment\",\n      \"pmids\": [\"20300119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define how Wnt signaling temporally couples to centrosome splitting\", \"Structural basis of C-Nap1 binding unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed cell-cycle control of AXIN2 abundance via APC/C-CDC20 degradation at G2/M, coupling Wnt signaling output to the cell cycle.\",\n      \"evidence\": \"Cell-cycle synchronization, CDC20 knockdown, CDC20-resistant conductin mutant, Wnt reporters, colony formation assays\",\n      \"pmids\": [\"22322943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degron sequence recognized by CDC20 not fully mapped\", \"Physiological consequence of cell-cycle Wnt oscillation in vivo unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated a context-dependent oncogenic role in which AXIN2 drives EMT and metastasis through Snail1 upregulation, contrary to its canonical tumor-suppressor activity.\",\n      \"evidence\": \"AXIN2 silencing in CRC cells, Snail1 and EMT marker assays, in vitro/in vivo invasion and metastasis assays\",\n      \"pmids\": [\"22745173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for the switch between suppressive and oncogenic roles not defined\", \"Whether Snail1 regulation is \\u03b2-catenin-dependent unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped the DIX domain as required for AXIN2's Wnt-inhibitory function, since DIX deletion converts AXIN2 into a pathway activator.\",\n      \"evidence\": \"Wild-type vs DIX-deleted AXIN2 overexpression with luciferase Wnt reporters in medulloblastoma cells\",\n      \"pmids\": [\"17373666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-domain deletion; does not reconcile DIX with the later-described RGS aggregon control of polymerization\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Positioned AXIN2 as a mediator of TGF-\\u03b2/Wnt cross-talk in chondrocytes through Smad3-dependent suppression of Axin expression.\",\n      \"evidence\": \"Axin2-/- and Smad3-/- chondrocytes, TGF-\\u03b2 treatment, Smad3 reporters, Axin/\\u03b2-catenin overexpression\",\n      \"pmids\": [\"18083923\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of Smad3-dependent Axin2 repression not detailed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established AXIN2 protein stability as a key tunable regulatory parameter, with tankyrase-dependent stabilization controlling tissue-specific Wnt output.\",\n      \"evidence\": \"ENU Axin2(canp) V26D stable allele, protein stability and tissue Wnt reporters, tankyrase inhibitor treatment of embryos; and OLP loss-of-function with XAV939 remyelination rescue\",\n      \"pmids\": [\"21555575\", \"21706018\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic basis for paradoxical tissue-specific Wnt activation unresolved\", \"Link between stability motif and tankyrase pathway not fully defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined transcriptional control of AXIN2 by Runx2-Hdac3 repression and CDX2 activation, embedding it in bone and intestinal regulatory circuits.\",\n      \"evidence\": \"ChIP for Runx2 and CDX2 binding, Hdac3-dependent repression assays, Axin2-/-:Runx2+/- rescue, intestinal enhancer reporters\",\n      \"pmids\": [\"23300083\", \"23393221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between repressive (Runx2) and activating (CDX2, \\u03b2-catenin) inputs at the locus not integrated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed AXIN1 and AXIN2 are non-equivalent in satellite cells, cooperating to suppress \\u03b2-catenin and maintain myoblast proliferation.\",\n      \"evidence\": \"siRNA knockdown of Axin1/Axin2 in WT and Axin2-null satellite cells, \\u03b2-catenin localization/reporter, \\u03b2-catenin rescue, proliferation/differentiation assays\",\n      \"pmids\": [\"25866367\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Apparent conflict with whole-animal functional equivalence not mechanistically reconciled\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Distinguished AXIN2 from AXIN1 by its selective requirement for degradasome formation, and defined a Rap1b-dependent BMP/FGF integration node in skeletal stem cells.\",\n      \"evidence\": \"siRNA depletion in SW480 cells with tankyrase inhibitor and degradasome imaging; Rap1b-null mice and Axin2+ stem cell BMP/FGF analysis\",\n      \"pmids\": [\"28107521\", \"28520221\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural determinant of AXIN2-specific degradasome nucleation unknown\", \"Direct biochemical link between Axin2 and Rap1b not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the RGS-domain aggregon as a polymerization brake whose neutralization enhances \\u03b2-catenin degradation, opening a therapeutic strategy in colorectal cancer.\",\n      \"evidence\": \"Axin1/Axin2 domain swapping, aggregon point mutagenesis, polymerization and \\u03b2-catenin degradation assays, peptide treatment, CRC growth assays\",\n      \"pmids\": [\"31534175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger of aggregon relief not yet identified in this study\", \"In vivo relevance of polymerization not established here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated post-transcriptional silencing of AXIN2 by TGF-\\u03b2-driven mRNA decay and m6A demethylation, linking AXIN2 loss to Wnt hyperactivation and immunosuppression.\",\n      \"evidence\": \"mRNA decay assays with tristetraprolin1 depletion and T\\u03b2RII\\u0394k-fib mice; meRIP-seq with ALKBH5 knockin mice and IGF2BP1 reader analysis in CRC\",\n      \"pmids\": [\"29409120\", \"37169182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How multiple RNA-level controls are prioritized in a given cell type unresolved\", \"Interaction between mRNA decay and translational 5'UTR control not integrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified G\\u03b1i2 as a partner that induces AXIN2 condensation by targeting the RGS aggregon, providing a druggable route to suppress Wnt signaling.\",\n      \"evidence\": \"G\\u03b1i2 overexpression/knockdown, condensation and \\u03b2-catenin degradation assays, Wnt reporters, guanabenz treatment, CRC mouse models\",\n      \"pmids\": [\"35115535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of G\\u03b1i2-aggregon engagement not resolved\", \"Upstream signals controlling G\\u03b1i2 availability not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expanded AXIN2's roles beyond Wnt by linking it to p53-dependent cell competition in neural progenitors and to ENO1-mediated metabolic control in neurons.\",\n      \"evidence\": \"Mosaic vs homogeneous Axin2 KO with Trp53 double KO and cortical phenotyping; Axin2/ENO1 co-interaction, XAV939 disruption, glycolysis and behavioral rescue in ASD models\",\n      \"pmids\": [\"37054704\", \"37078424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Axin2 post-transcriptionally suppresses p53 unknown\", \"Whether ENO1 binding is Wnt-dependent unclear\", \"Direct biochemical AXIN2-ENO1 interface not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AXIN2's many regulatory layers \\u2014 transcriptional, translational, mRNA-decay, m6A, cell-cycle degradation, and aggregon-controlled polymerization \\u2014 are integrated in vivo to select between its Wnt-scaffold, centrosomal, metabolic, and p53-suppressive functions remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model reconciling pro- and anti-tumorigenic roles\", \"Determinants of functional partner choice (destruction complex vs C-Nap1 vs ENO1) unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 16, 14, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 4, 6, 14, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 16, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 8, 10, 19]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [6, 4]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [13, 22, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 14, 15, 22]}\n    ],\n    \"complexes\": [\"\\u03b2-catenin destruction complex / degradasome\"],\n    \"partners\": [\"CTNNB1\", \"C-Nap1 (CEP250)\", \"CDC20\", \"GNAI2\", \"ENO1\", \"APC\", \"GSK3B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}